Detail akcie Citius Onco Rg online

Business Summary: Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, Citius Oncology Inc revenues was not reported. Net loss increased 17% to $24.8M. Higher net loss reflects Research and development increase of 30% to $6.4M (expense), Stock-based compensation general and ad increase of 11% to $8.3M (expense), General and administrative increase of 8% to $8.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.31 to -$0.34.